Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Decreases By 16.6%

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 307,305 shares, a decline of 16.6% from the January 15th total of 368,545 shares. Based on an average daily trading volume, of 196,885 shares, the short-interest ratio is currently 1.6 days. Currently, 0.4% of the shares of the company are short sold. Currently, 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 196,885 shares, the short-interest ratio is currently 1.6 days.

Wall Street Analysts Forecast Growth

NAUT has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Thursday, January 22nd. Wall Street Zen upgraded Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 18th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell” and an average target price of $2.50.

Institutional Investors Weigh In On Nautilus Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its stake in Nautilus Biotechnology by 5.4% during the fourth quarter. Millennium Management LLC now owns 1,019,996 shares of the company’s stock worth $1,989,000 after buying an additional 52,448 shares during the last quarter. Bridgeway Capital Management LLC raised its holdings in shares of Nautilus Biotechnology by 4.0% during the 4th quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock worth $254,000 after acquiring an additional 5,000 shares during the period. Captrust Financial Advisors acquired a new position in shares of Nautilus Biotechnology during the 4th quarter valued at about $66,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Nautilus Biotechnology in the fourth quarter valued at about $204,000. Finally, Marshall Wace LLP purchased a new stake in shares of Nautilus Biotechnology in the fourth quarter valued at about $228,000. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Trading Down 0.4%

NASDAQ:NAUT traded down $0.01 during trading hours on Wednesday, hitting $2.68. 376,203 shares of the stock were exchanged, compared to its average volume of 219,556. The firm’s fifty day moving average price is $2.03 and its 200 day moving average price is $1.48. Nautilus Biotechnology has a 52-week low of $0.62 and a 52-week high of $2.85. The company has a market cap of $338.51 million, a P/E ratio of -5.36 and a beta of 1.49.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.